A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

August 9, 2004

Primary Completion Date

January 8, 2007

Study Completion Date

January 8, 2007

Conditions
Heart Transplantation
Interventions
DRUG

Everolimus (Certican)

Trial Locations (28)

1090

Vienna

4032

Chermside

6020

Innsbruck

10032

New York Presbyterian Medical Center, New York

15006

A Coruña

19104

University of Pennsylvania Medical Center, Philadelphia

19140

Temple University Hospital, Philadelphia

20162

Milan

24105

Kiel

27710

Duke Clinical Research Institute, Durham

33006

Oviedo

33606

Tampa General Hospital, Tampa

53215

St Luke's Medical Center, Milwaukee

55455

University of Minnesota, Minneapolis

77030

Texas Heart Institute/St Lukes Hospital, Houston

The Baylor College of Medicine/ The Methodist Hospital, Houston

80131

Napoli

900048

Cedar Sinai Medical Center, Los Angeles

35294-0006

The University of Alabama at Birmingham, Birmingham

07102

Newark Beth Israel Medical Center, Newark

NSW2010

Darlinghurst

Unknown

Belo Horizonte

Vancouver

Hanover

05403-000

São Paulo

M5G 2C4

Toronto

08036

Barcelona

08907

Llobregat

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY